Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Dose Escalation Trial of GEN1057 in Advanced Malignant Solid Tumors
jRCT2031240508Phase 1Active, not recruiting
- Sponsor
- Genmab
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of GEN1057 in Non-hematologic malignancy, sponsored by Genmab. Primary endpoints: Safety and tolerability of GEN1057 - incidence and severity of adverse events and laboratory abnormalities and Incidence of dose-limiting toxicities (DLTs). Started Jan 2025; status: active, not recruiting.
02
Drugs
GEN1057
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2031240508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240508.